Cargando…
Characterization of the 5-HT(2C) receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity
The 5-HT(2C) receptor agonist lorcaserin (Belviq®) has been Food and Drug Administration (FDA) approved for the treatment of obesity. The present study is a back translational investigation into the effect of 28-day lorcaserin treatment in a diet-induced obesity (DIO) model using male, Sprague–Dawle...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317222/ https://www.ncbi.nlm.nih.gov/pubmed/25692009 http://dx.doi.org/10.1002/prp2.84 |